Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Net Cash Flow (2018 - 2025)

Historic Net Cash Flow for TransMedics (TMDX) over the last 8 years, with Q3 2025 value amounting to $65.6 million.

  • TransMedics' Net Cash Flow rose 29849.89% to $65.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $135.6 million, marking a year-over-year increase of 23912.62%. This contributed to the annual value of -$57.6 million for FY2024, which is 12979.06% down from last year.
  • Per TransMedics' latest filing, its Net Cash Flow stood at $65.6 million for Q3 2025, which was up 29849.89% from $89.6 million recorded in Q2 2025.
  • TransMedics' 5-year Net Cash Flow high stood at $386.8 million for Q2 2023, and its period low was -$155.2 million during Q3 2023.
  • Moreover, its 5-year median value for Net Cash Flow was -$1.5 million (2021), whereas its average is $23.3 million.
  • As far as peak fluctuations go, TransMedics' Net Cash Flow soared by 682127.74% in 2022, and later plummeted by 77279.06% in 2023.
  • Over the past 5 years, TransMedics' Net Cash Flow (Quarter) stood at $3.4 million in 2021, then crashed by 210.18% to -$3.7 million in 2022, then tumbled by 772.79% to -$32.6 million in 2023, then soared by 122.22% to $7.2 million in 2024, then soared by 805.56% to $65.6 million in 2025.
  • Its Net Cash Flow was $65.6 million in Q3 2025, compared to $89.6 million in Q2 2025 and -$26.9 million in Q1 2025.